

PRESS RELEASE

Dr. Alfred Merz Appointed Chief Executive Officer of ProBioGen

Berlin, Germany - March 31, 2025

ProBioGen announces the appointment of Dr. Alfred Merz, PhD, as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Merz, who previously served as Chief Operating Officer (COO) and interim CEO, now assumes full leadership of the company.

Dr. Alfred Merz joined ProBioGen in 2024 from Bayer Pharmaceuticals, where he held the position of Senior Vice President and Head of Product Supply Medical Devices. With over 30 years of international experience in manufacturing, operational excellence, and strategy development, Dr. Merz has worked for leading pharmaceutical and biotech companies, including Bayer and Novartis. His expertise will be instrumental in driving the company's next growth phase, while solidifying ProBioGen's position as a trusted partner in biopharmaceutical development and manufacturing for clinical and commercial supply, recognized for its scientific acumen, client-oriented flexibility, and reliability.

"ProBioGen has a strong legacy of innovation and excellence in CDMO services and technologies," said Dr. Alfred Merz. "I am honored to lead this outstanding team as we accelerate our growth, expand our capabilities, and continue delivering high-quality solutions for our pharma and biotech partners."

"Alfred embodies impressive leadership and business acumen," stated Dr. Wafik Bardissi, Chairman of ProBioGen's Supervisory Board and CEO of Minapharm Pharmaceuticals SAE. "His strategic expertise is vital to accelerating ProBioGen's growth, advancing therapeutic innovation globally through proprietary technologies, and fostering impactful partnerships while enhancing operational excellence."

With Dr. Merz at the helm, ProBioGen is well-positioned to continue its legacy and enter the next phase of growth. As a leading CDMO provider for biologics and advanced therapies, ProBioGen offers comprehensive services paired with cutting-edge technologies, ensuring on-time delivery, top quality, and tailored solutions. The customer-centric company remains committed to driving innovation and meeting the growing demand for life-saving biopharmaceuticals, setting the standard for accelerated development in the industry.

About ProBioGen

[ProBioGen](#) is a Berlin-based biotech company, a so-called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.

It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, while also developing and outlicensing proprietary technologies that enhance product quality and features. Founded in 1994 as a spin-off of Charité, a widely recognized hospital known as one [of the best](#) in the world. 30 years later, almost 300 employees work at ProBioGen's three locations in Berlin.

Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisitions. Diversification is a complementary driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

For more information about ProBioGen, follow us on [LinkedIn](#).

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer
cdmo@probiogen.de

ProBioGen Press Contact:

Sarah Wandrey
Senior Communications Manager
press@probiogen.de